glp‑1 weight‑loss drugs
Cut Prescription Weight Loss Bills To Zero
A new analysis predicts that GLP-1 weight-loss drugs could double Medicare’s prescription drug spending within the next decade, showing that cutting prescription weight-loss bills to zero would require sweeping reforms. The drugs, including semaglutide and tirzepatide, are now part of Medicare Part D, driving premiums higher for seniors. Medical